已出刊文章

【綜合評述】慢性手部濕疹治療新進展:局部Janus激酶抑制劑—Delgocitinib
Recent Advances in the Treatment of Chronic Hand Eczema: Topical Janus Kinase Inhibitor—Delgocitinib
Janus激酶抑制劑、慢性手部濕疹、delgocitinib、Janus kinase inhibitor, chronic hand eczema, delgocitinib
王建贏 Jian-Ying Wang1 、許珊瑜 Shan-Yu Hsu1,*
1新北市立聯合醫院藥劑科

摘要
慢性手部濕疹(chronic hand eczema, CHE) 為一種常見且反覆發作的慢性發炎性皮膚疾病,臨床上定義為病程超過3個月,或1年內復發達2次以上。其病因多樣,與職業性暴露、環境刺激、接觸性過敏反應及異位性體質密切相關。
CHE的治療通常採階梯式策略,初期以保濕與避免刺激物為主,進一步可使用局部類固醇、鈣調神經磷酸酶抑制劑、光療,或進展至系統性藥物。然而,部分病人對既有療法反應不佳,或因副作用限制使用,長期病程控制仍具挑戰。2025年,美國食品藥物管理局核准首款用於中重度CHE的外用Janus激酶抑制劑(Janus kinase inhibitor)–delgocitinib乳膏。
DELTA 系列第三期研究顯示,delgocitinib於DELTA 1/2可顯著改善整體嚴重度、主觀症狀(搔癢、疼痛)與生活品質,且在DELTA 3最長52週治療期間具良好耐受性與安全性;此外,DELTA FORCE試驗亦證實其在療效與安全性方面均優於口服alitretinoin,為中重度CHE提供新的長期治療選擇。
 
ABSTRACT
Chronic hand eczema (CHE) is a common and recurrent chronic inflammatory skin disease, clinically defined as a disease course lasting more than 3 months or relapsing at least twice within one year. Its etiology is multifactorial and closely associated with occupational exposure, environmental irritants, contact allergies, and atopic predisposition.
Treatment of CHE generally follows a stepwise approach, beginning with moisturization and avoidance of irritants. Further management may include topical corticosteroids, calcineurin inhibitors, phototherapy, or progression to systemic medications. However, some patients respond poorly to existing therapies or experience limitations due to adverse effects, making long-term disease control challenging.
In 2025, the U.S. Food and Drug Administration approved the first topical Janus kinase inhibitor–delgocitinib cream for moderate-to-severe CHE. Across the phase III DELTA program, delgocitinib significantly improved overall disease severity, patient-reported symptoms (pruritus and pain), and quality-of-life in DELTA-1 and DELTA-2; in the open-label DELTA-3 extension, up to 52 weeks of treatment was well tolerated with no new safety signals. In the DELTA FORCE trial, delgocitinib demonstrated superior efficacy and a more favorable safety profile versus oral alitretinoin, providing a new long-term treatment option for adults with moderate-to-severe CHE.
 
Submitted for publication: 2025.08.12; Accepted for publication: 2026.02.27

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×